Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Dr Burke on CLL Treatment Challenges in Community vs Academic Health Care Settings

May 30th 2025

John M. Burke, MD, discusses the challenges associated with using venetoclax for CLL management across both community and academic oncology settings.

Fixed-Duration Bispecific Antibodies Are Effective, Safe, and Convenient for Follicular Lymphoma

May 29th 2025

Vivek Patel, MD, discusses the safety of bispecific antibodies and the choice between these agents and CAR T-cell therapy for follicular lymphoma.

Neoantigen-Reactive TILs With CISH Knockout Are Safe and Effective in Metastatic GI Tumors

May 29th 2025

CRISPR-Cas9–mediated CISH gene knockout TIL therapy was well tolerated and demonstrated early signals of efficacy in metastatic GI epithelial cancer.

Dr Bardia on Efficacy Data from the DESTINY-Breast06 Trial of T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer

May 29th 2025

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in patients with HER2-low and -ultralow unresectable or metastatic breast cancer.

Dr Kahlon on the Availability of Generic Eltrombopag for Anemia & Thrombocytopenia

May 29th 2025

Kanwarpal S. Kahlon, MD, discusses the benefits of the availability of generic eltrombopag formulations for aplastic anemia and immune thrombocytopenia.

Pelabresib/Ruxolitinib Improves Spleen Responses in JAK Inhibitor–Naive Myelofibrosis

May 29th 2025

The addition of pelabresib to ruxolitinib generated a significant improvement in spleen response in patients with JAK inhibitor–naive myelofibrosis.

FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD

May 28th 2025

Dr Galsky discusses the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab monotherapy for MIBC.

FDA Grants Priority Review to Sevabertinib for HER2-Mutant NSCLC

May 28th 2025

The FDA granted priority review to sevabertinib for pretreated, advanced non–small cell lung cancer harboring HER2 mutations.

Elotuzumab Plus PVd Has Antitumor Activity in Heavily Pretreated R/R Myeloma

May 28th 2025

Elotuzumab plus PVd elicited responses in patients with relapsed/refractory multiple myeloma after a median of 3 prior lines of therapy.

Dr Tarantino on Directions for Prospective Research in HER2+ Metastatic Breast Cancer

May 27th 2025

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

Dr Bowman on Distinctions Between Disease Characteristics and Treatment Response in ccRCC vs Non-ccRCC

May 27th 2025

I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.

Bispecific Antibodies Gain Ground in Frontline Follicular Lymphoma Management

May 27th 2025

Vivek Patel, MD, discusses the evolving roles of chemoimmunotherapy and bispecific antibodies in the first-line follicular lymphoma setting.

CHMP Recommends EU Approval of Frontline Tislelizumab/Chemo for Metastatic Nasopharyngeal Carcinoma

May 27th 2025

The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.

Eftilagimod Alfa/Radiotherapy/Pembrolizumab Yields Favorable Hyalinization/Fibrosis in Soft Tissue Sarcoma

May 27th 2025

Eftilagimod alfa plus radiotherapy and pembrolizumab improved tumor hyalinization/fibrosis rates vs radiotherapy alone in resectable soft tissue sarcoma.

CHMP Recommends EU Approval of Perioperative Durvalumab for Muscle-Invasive Bladder Cancer

May 27th 2025

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD

May 26th 2025

Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.

SVR With Pacritinib Is Linked With OS Benefit in Myelofibrosis With Thrombocytopenia

May 26th 2025

SVR10 at week 12 was associated with favorable OS among patients with myelofibrosis and thrombocytopenia treated with pacritinib in the PERSIST-2 trial.

Post Hoc Data Show Anemia Benefits, Reduced Transfusion Burden With Momelotinib in Myelofibrosis

May 24th 2025

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

Dr Ip on the Limitations of Real-World CAR T-Cell Therapy Research in LBCL

May 23rd 2025

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.

Dr Ghia on OS Outcomes With Ibrutinib/Venetoclax in CLL Relative to a Matched Healthy Population

May 23rd 2025

Paolo Ghia, MD, PhD, discusses the rationale for conducting an OS analysis of fixed-duration ibrutinib plus venetoclax in patients with CLL.